|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||47609.17 g·mol−1|
|(what is this?)|
Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system. It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets.  The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab, American Medical Association.
- Lodish H, Berk A, Matsudaira P, Kaiser CA, Krieger M, Scott MP, Zipursky L, Darnell J (2003). Molecular cell biology (5th ed.). New York: W.H. Freeman. p. 973. ISBN 978-0-7167-4366-8.